TC
RXRX icon

Titleist Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Titleist Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-38,200
Closed -$654K – 282
2021
Q4 		$654K Buy
+38,200
New +$719K 0.13% 120

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Titleist Capital's RXRX Position: Q4 2022 in Review

Titleist Capital held its Recursion Pharmaceuticals (RXRX) position steady in Q4 2022 at 35,750 shares worth $276K. The position accounts for 0.06% of the portfolio, ranked #188.

Titleist Capital first reported a position in RXRX in Q4 2021 and has held it in 5 quarters since. The position peaked at $643K in Q4 2021. 144 funds tracked by Wall St. Rank hold RXRX as of Q4 2022.

  • Titleist Capital held 35,750 shares of Recursion Pharmaceuticals worth $276K as of Q4 2022.
  • Titleist Capital left its Recursion Pharmaceuticals share count unchanged in Q4 2022.
  • Recursion Pharmaceuticals made up 0.06% of Titleist Capital's portfolio in Q4 2022, its #188 holding.
  • Titleist Capital first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
  • Titleist Capital's Recursion Pharmaceuticals position peaked at $643K in Q4 2021.
  • 144 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2022.

Based on Titleist Capital's 13F filing for Q4 2022, filed 12 Jan 2023.